

This material is an English translation of the press release announced on March 28, 2018 in Japanese, and the Japanese release is given priority about the content and the interpretation.

March 28, 2018

Notice of Revision of Financial Forecast

Hisamitsu Pharmaceutical Co., Inc., (Chairman and CEO: Hirotaka Nakatomi) announces as follows, the revision of consolidated financial forecast of the fiscal year ending February 28, 2018, which had been released on April 7, 2017.

1.Revision of Consolidated Financial Forecast

Revised Consolidated Financial Forecast of Fiscal Year Ending February 28, 2018

(March 1, 2017, through February 28, 2018)

(Amounts in millions of yen, except amounts per share in yen)

	Net Sales	Operating Income	Ordinary Income	Net Income	Net Income per Share
Previous Forecast (A)	147,000	24,100	25,600	18,500	218.85 yen
Revised Forecast (B)	148,000	26,500	28,400	19,200	229.49 yen
Variance in Amount (B-A)	+1,000	+2,400	+2,800	+700	
Variance in Percentage (%)	+ 0.7%	+10.0%	+10.9%	+ 3.8%	
*Ref. Results of Prior Fiscal Year (Fiscal Year Ended February 28, 2017)	145,925	26,306	28,179	20,395	241.27 yen

2. Reasons for the Revision

The reason for revising the consolidated financial forecast of fiscal year ending February 28, 2018 is that the operating income and, ordinary income are expected to exceed the figures contained in the previous forecast. Gross profit increased due to growth in sales and, selling, general and administrative expenses is less than the forecast.

Extraordinary income is less than the forecast as we impaired part of tangible fixed assets.

As a result, net income is expected to exceed the figures contained in the previous forecast.

* The financial forecasts described above are prepared on the basis of information available as of the date of this announcement. Actual financial results may differ from those included in these financial forecasts due to a variety of factors going forward.